Publikationen, an denen er mitarbeitet Eduardo Tolosa Sarró (36)

2024

  1. Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials

    Movement Disorders

  2. Mitochondrial DNA deletions in the cerebrospinal fluid of patients with idiopathic REM sleep behaviour disorder

    eBioMedicine, Vol. 102

2023

  1. Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease

    npj Parkinson's Disease, Vol. 9, Núm. 1

  2. Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort

    Movement Disorders, Vol. 38, Núm. 2, pp. 286-303

2022

  1. Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort

    npj Parkinson's Disease, Vol. 8, Núm. 1

2021

  1. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome

    Nature Communications, Vol. 12, Núm. 1

  2. Human-lineage-specific genomic elements are associated with neurodegenerative disease and APOE transcript usage

    Nature Communications, Vol. 12, Núm. 1

  3. Identification of sixteen novel candidate genes for late onset Parkinson’s disease

    Molecular Neurodegeneration, Vol. 16, Núm. 1

  4. Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease

    Annals of Neurology, Vol. 90, Núm. 1, pp. 35-42

  5. Magnetic resonance imaging abnormalities as a marker of multiple system atrophy in isolated rapid eye movement sleep behavior disorder

    Sleep, Vol. 44, Núm. 1, pp. 1-9

  6. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils

    Acta Neuropathologica, Vol. 142, Núm. 3, pp. 475-494

2020

  1. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

    The Lancet Neurology, Vol. 19, Núm. 1, pp. 71-80

  2. Dystonia genes functionally converge in specific neurons and share neurobiology with psychiatric disorders

    Brain, Vol. 143, Núm. 9, pp. 2771-2787

  3. Lack of Asymmetry of Nigrostriatal Dopaminergic Function in Healthy Subjects

    Movement Disorders, Vol. 35, Núm. 6, pp. 1072-1076

  4. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients

    Annals of Clinical and Translational Neurology, Vol. 7, Núm. 10, pp. 1816-1830

  5. Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance

    Movement Disorders, Vol. 35, Núm. 10, pp. 1755-1764

  6. Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information

    Nature Communications, Vol. 11, Núm. 1

2019

  1. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

    Movement Disorders, Vol. 34, Núm. 9, pp. 1392-1398

  2. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)

    Parkinsonism and Related Disorders, Vol. 62, pp. 201-209

  3. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

    The Lancet Neurology, Vol. 18, Núm. 12, pp. 1091-1102